Humacyte Inc expected to post a loss of 25 cents a share - Earnings Preview

Humacyte

21/03/2025 13:08

Humacyte Inc HUMA.OQ HUMA.O is expected to show a rise in quarterly revenue when it reports  results on March 24 (estimated) for the period ending December 31 2024

The Durham North Carolina-based  company is expected to report revenue of $214.29 thousand, according to the mean estimate from 7 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Humacyte Inc is for a loss of 25 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Humacyte Inc is $10.00‚Äč, above‚Äč its last closing price of $3.18. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.25
-0.25
-0.33
Missed
-32.8
Jun. 30 2024
-0.24
-0.24
-0.48
Missed
-101.7
Mar. 31 2024
-0.22
-0.22
-0.29
Missed
-28.9‚Äč
Dec. 31 2023
-0.25
-0.24
-0.24
Met
2
‚Äč‚ÄčSep. 30 2023
-0.25
-0.25
-0.25
Met
1.3
Jun. 30 2023
-0.22
-0.22
-0.22
Met
-0.1‚Äč
Mar. 31 2023
-0.21
-0.21
-0.36
Missed
-71.8
Dec. 31 2022
-0.23
-0.04
Beat
83

This summary was machine generated March 21 at 13:08 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)